Disclaimer: This information is intended for educational purposes and as a clinical reference for healthcare professionals. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider for any health concerns or before making any decisions related to patient care. Clinical judgment, patient-specific factors, and the latest evidence should always guide clinical practice.

Composition Of Ferrous Sulphate

Overview

• Definition: Ferrous sulphate (FeSO₄) is an inorganic salt of iron, commonly used as an oral iron supplement for the prevention and treatment of iron deficiency and iron deficiency anemia. Its composition refers to its chemical structure and, crucially, its elemental iron content, which dictates its therapeutic efficacy.
• Epidemiology: While the composition of ferrous sulphate itself is a chemical constant, its clinical relevance is tied to the epidemiology of iron deficiency. Iron deficiency is the most common micronutrient deficiency globally, affecting an estimated 1.2 billion people, with the highest prevalence in children and women of reproductive age, particularly in low-income countries. Ferrous sulphate is one of the most widely used and cost-effective agents to address this deficiency.
• Classification: Ferrous sulphate primarily exists in two forms relevant to clinical practice:
  • Ferrous sulphate anhydrous (FeSO₄): Lacks water molecules.
  • Ferrous sulphate heptahydrate (FeSO₄·7H₂O): The most common and readily available form, containing seven molecules of water of crystallization. This hydrated form is typically what is referred to when "ferrous sulphate" is mentioned in clinical contexts. Other less common hydrates (e.g., monohydrate) exist but are less frequently used in pharmaceuticals.

Pathophysiology (Pharmacological Mechanism Related to Composition)

• Mechanism: The "composition" of ferrous sulphate, specifically its ferrous (Fe²⁺) state, is critical to its therapeutic mechanism. Ferrous sulphate provides iron in its bivalent (Fe²⁺) form, which is the most readily absorbed form of non-heme iron in the duodenum. Once absorbed, this iron is transported in the blood bound to transferrin and primarily utilized in the bone marrow for hemoglobin synthesis. Iron is an essential component of heme, which, in turn, is a critical part of hemoglobin, the protein responsible for oxygen transport in red blood cells. The availability of absorbable iron from ferrous sulphate directly supports erythropoiesis and reverses iron deficiency anemia.
• Risk Factors (for Iron Deficiency, managed by Ferrous Sulphate):
  • Inadequate dietary iron intake (e.g., vegetarian/vegan diets, malnutrition).
  • Increased iron requirements (e.g., pregnancy, lactation, rapid growth in infancy/adolescence).
  • Increased iron loss (e.g., chronic blood loss from menstruation, gastrointestinal bleeding from NSAIDs, peptic ulcers, diverticulosis, colon cancer).
  • Impaired iron absorption (e.g., celiac disease, inflammatory bowel disease, gastric bypass surgery, H. pylori infection, achlorhydria).
• Protective Factors (against Iron Deficiency):
  • Adequate dietary iron intake (heme iron from meat, poultry, fish; non-heme iron from plants fortified with vitamin C).
  • Avoidance of chronic blood loss.
  • Appropriate management of gastrointestinal disorders affecting absorption.

Clinical Presentation (Not applicable to the composition itself, but related to Iron Deficiency Anemia)

Signs and Symptoms (of Iron Deficiency Anemia)

• Cardinal Features: Fatigue, pallor, weakness, dyspnea on exertion, reduced exercise tolerance.
• Early Signs: Often asymptomatic or mild fatigue.
• Advanced Signs: Severe pallor (conjunctivae, nail beds), glossitis, cheilosis, koilonychia (spoon nails), pica (craving for non-nutritive substances like ice, dirt), restless legs syndrome.
• Atypical Presentations: Impaired cognitive function, poor immune response, impaired thermoregulation, hair loss.

Physical Examination (for Iron Deficiency Anemia)

• Inspection: Pallor of skin, conjunctivae, mucous membranes, nail beds. Angular cheilosis, atrophic glossitis.
• Palpation: Koilonychia (brittle, spoon-shaped nails). Rarely, splenomegaly in severe, chronic cases.
• Special Tests: N/A for physical exam of IDA itself.

Diagnostic Approach (for Iron Deficiency Anemia)

History Taking

• Key Questions: Dietary habits (vegetarian/vegan), menstrual history (menorrhagia), history of blood loss (GI bleeding, epistaxis, frequent donations), previous surgeries (gastric bypass), symptoms of malabsorption (diarrhea, steatorrhea), family history of anemia.
• Red Flags: Melena, hematochezia, unexplained weight loss, new onset GI symptoms in older adults (suggesting malignancy).

Laboratory Tests

• First-Line:
  • Complete Blood Count (CBC): Low hemoglobin (Hb) and hematocrit (Hct), microcytic (low MCV <80 fL), hypochromic (low MCH, MCHC) red blood cells, elevated Red Cell Distribution Width (RDW).
  • Serum Ferritin: The most sensitive and specific test for iron stores. A level <30 ng/mL (or <15 ng/mL in some labs) is diagnostic of iron deficiency. (Note: Ferritin can be elevated in inflammatory conditions, masking deficiency).
  • Total Iron Binding Capacity (TIBC): Elevated.
  • Serum Iron: Low.
  • Transferrin Saturation (TSAT): Low (<16-20%).
• Confirmatory:
  • If ferritin is equivocal (e.g., in inflammation), a trial of oral iron and subsequent rise in Hb and ferritin can be diagnostic. Bone marrow biopsy for iron stores is rarely needed.
• Monitoring:
  • Hb/Hct: Monthly after starting iron therapy to assess response. Expected rise of 1-2 g/dL over 3-4 weeks.
  • Ferritin: After 3-6 months of therapy (or after Hb normalizes) to confirm repletion of iron stores. Target ferritin >50 ng/mL, ideally >100 ng/mL.

Imaging (for underlying causes of Iron Deficiency Anemia)

• Recommended:
  • Endoscopy/colonoscopy if GI blood loss is suspected and no obvious cause (e.g., menorrhagia) is found, especially in men and postmenopausal women.
  • Capsule endoscopy for small bowel evaluation if upper and lower endoscopy are negative.
• Advanced: N/A for iron deficiency itself.

Management (Focus on Dosing based on Ferrous Sulphate Composition)

Elemental Iron Content of Ferrous Sulphate

The "composition" of ferrous sulphate dictates its elemental iron content, which is the most crucial factor for dosing:

• Ferrous Sulphate Heptahydrate (FeSO₄·7H₂O):

  • Molecular Weight: 278.01 g/mol
  • Elemental Iron (Fe) Weight: 55.845 g/mol
  • Elemental Iron Content: Approximately 20% by weight.
  • Example: A 325 mg tablet of ferrous sulphate heptahydrate contains approximately 65 mg of elemental iron.

• Ferrous Sulphate Anhydrous (FeSO₄):

  • Molecular Weight: 151.91 g/mol
  • Elemental Iron (Fe) Weight: 55.845 g/mol
  • Elemental Iron Content: Approximately 33% by weight.
  • Example: A 200 mg tablet of ferrous sulphate anhydrous contains approximately 65 mg of elemental iron.

Clinical Significance: Always prescribe and administer oral iron supplements based on their elemental iron content, not the salt weight.

Acute Management (of severe Iron Deficiency Anemia, not composition)

• Immediate: In severe, symptomatic anemia (e.g., Hb <7-8 g/dL with symptoms, or cardiovascular instability), immediate intervention may include blood transfusion. This is not directly related to the composition of ferrous sulphate but its clinical use context.
• Stabilization: Address underlying cause of blood loss if present. Start oral iron therapy.
• Emergency: For iron poisoning (e.g., accidental ingestion by children), chelation therapy (deferoxamine) may be required. This is an acute toxicity of the iron component, not the sulphate.

Chronic Management (Pharmacological, related to Ferrous Sulphate)

• Pharmacological:
  • Oral Iron Therapy: Ferrous sulphate is the most commonly used and recommended oral iron salt due to its low cost, good efficacy, and tolerability profile.
    • Standard Adult Dose (for iron deficiency anemia): 150-200 mg elemental iron per day, typically divided into 1-2 doses.
      • Practical Application: This usually translates to one 325 mg tablet of ferrous sulphate heptahydrate (providing ~65 mg elemental iron) given 2-3 times daily.
    • Prevention Dose (e.g., pregnancy): 30-60 mg elemental iron daily.
      • Practical Application: One 325 mg tablet of ferrous sulphate heptahydrate daily.
  • Administration: Best absorbed on an empty stomach (1 hour before or 2 hours after meals) with vitamin C (e.g., orange juice) to enhance absorption. If gastrointestinal side effects occur, it can be taken with food, although absorption may be slightly reduced.
  • Duration: Therapy usually continues for 3-6 months after hemoglobin levels normalize to replenish iron stores (ferritin >50-100 ng/mL).
• Non-pharmacological (Adjunctive, related to Iron Deficiency):
  • Dietary counseling for iron-rich foods.
  • Identification and treatment of underlying causes of iron deficiency (e.g., H. pylori eradication, management of menorrhagia, GI investigations).
• Monitoring: (See Diagnostic Approach -> Monitoring above).

Treatment Algorithms (for Iron Deficiency Anemia)

• First-Line: Oral ferrous sulphate (150-200 mg elemental iron daily) for 3-6 months after Hb normalization.
• Second-Line (for intolerance or malabsorption):
  • Alternative oral iron salts (e.g., ferrous gluconate, ferrous fumarate) may be tried if ferrous sulphate causes intolerable side effects. They typically have lower elemental iron content per tablet, requiring higher salt doses to achieve the same elemental iron dose.
  • Reduced dosing frequency (e.g., every other day) may improve tolerance and even absorption due to reduced hepcidin response.
• Refractory Cases:
  • If oral iron fails (Hb does not rise appropriately, or iron stores remain depleted despite good adherence and ruling out ongoing blood loss/malabsorption):
    • Re-evaluate diagnosis, adherence, and absorption.
    • Consider intravenous (IV) iron therapy (e.g., iron sucrose, ferric carboxymaltose) for severe malabsorption, significant intolerance, ongoing major blood loss, or severe disease requiring rapid iron repletion.

Complications (Related to Iron component of Ferrous Sulphate)

• Common:
  • Gastrointestinal upset (nausea, abdominal discomfort, constipation, diarrhea). These are dose-dependent and can often be mitigated by starting with a lower dose, taking with food, or switching to an every-other-day regimen.
  • Darkening of stools (a benign effect due to unabsorbed iron).
• Serious:
  • Iron Poisoning (Toxicity): Especially in children who may ingest adult-sized iron pills. Can lead to severe GI upset, metabolic acidosis, cardiovascular collapse, liver damage, and death. Symptoms include vomiting, diarrhea, abdominal pain, hematemesis, lethargy.
  • Hemochromatosis: In individuals with genetic predispositions (e.g., HFE gene mutations), chronic iron supplementation can exacerbate iron overload, leading to organ damage (liver, heart, pancreas).
  • Drug Interactions: Reduced absorption of fluoroquinolones, tetracyclines, levothyroxine, bisphosphonates due to chelation with iron. Conversely, iron absorption can be reduced by antacids, proton pump inhibitors, calcium, and phytates.

Prognosis (for Iron Deficiency Anemia treated with Ferrous Sulphate)

• Factors: Prognosis for iron deficiency anemia treated with ferrous sulphate is generally excellent, provided the underlying cause is identified and managed, and adherence to therapy is good. Factors affecting outcome include severity of anemia, presence of ongoing blood loss, malabsorption, and patient adherence to iron therapy.
• Survival: Iron deficiency anemia itself rarely directly causes mortality unless very severe and leading to cardiac decompensation. Treatment with ferrous sulphate significantly improves morbidity and quality of life.
• Quality of Life: Improves significantly with resolution of anemia, leading to increased energy, improved cognitive function, and resolution of symptoms like restless legs and pica.

Prevention (of Iron Deficiency, using Ferrous Sulphate)

• Primary:
  • Dietary counseling, especially for at-risk populations (vegetarians, pregnant women).
  • Iron-fortified foods (cereals, flours).
  • Prophylactic iron supplementation in high-risk groups (e.g., pregnant women, infants in certain settings, menstruating women with heavy periods).
    • Dose for prophylaxis in pregnancy: 30-60 mg elemental iron daily (e.g., one 325 mg ferrous sulphate tablet).
• Secondary: Early screening for iron deficiency in at-risk populations and prompt treatment to prevent progression to anemia.
• Tertiary: Preventing complications of severe, prolonged iron deficiency (e.g., cardiovascular effects, impaired development in children) by ensuring adequate and sustained iron repletion.

Special Populations (considerations for using Ferrous Sulphate)

• Pediatric: Iron requirements are high during rapid growth. Dose is based on elemental iron (typically 3-6 mg elemental iron/kg/day divided 1-3 times daily). Ferrous sulphate liquid preparations are available. Careful dosing is essential to avoid overdose, which is particularly dangerous in children.
• Geriatric: Older adults are at increased risk for iron deficiency due to chronic diseases, malabsorption, and occult GI bleeding. Investigations for the cause of iron deficiency are crucial. Tolerability of oral iron may be an issue; lower initial doses or every-other-day dosing may be beneficial.
• Pregnancy: Increased iron requirements due to fetal growth, placental development, and expansion of maternal blood volume. Prophylactic iron (30-60 mg elemental iron daily) is often recommended. If iron deficiency anemia develops, treatment doses (100-200 mg elemental iron daily) are required. Ferrous sulphate is safe and effective in pregnancy.
• Comorbidities:
  • Inflammatory Bowel Disease (IBD): Malabsorption and chronic blood loss are common. Oral iron may be poorly tolerated or ineffective due to inflammation or rapid transit. IV iron may be preferred.
  • Chronic Kidney Disease (CKD): Often presents with iron deficiency. Oral iron may be used, but IV iron is frequently required, especially in patients on hemodialysis or those receiving erythropoiesis-stimulating agents (ESAs).
  • Gastric Bypass Surgery: High risk of iron malabsorption. Requires close monitoring and often higher doses of oral iron or IV iron.

Clinical Pearls

• Diagnostic: Always consider the elemental iron content when prescribing ferrous sulphate. A 325 mg ferrous sulphate tablet (heptahydrate) contains ~65 mg elemental iron.
• Treatment: Ferrous sulphate remains the first-line and most cost-effective oral iron supplement. Start low and go slow to minimize GI side effects. Administering with vitamin C enhances absorption.
• Pitfalls:
  • Failing to investigate the underlying cause of iron deficiency, especially in men and postmenopausal women, can delay diagnosis of serious conditions like GI malignancy.
  • Stopping iron too soon: Patients need to replete iron stores, not just normalize Hb. Continue therapy for 3-6 months after Hb normalization.
  • Miscalculating elemental iron dose, leading to under-dosing or increased side effects.

Recent Updates

• Guidelines: Current guidelines from organizations like the World Health Organization (WHO), American Society of Hematology (ASH), and National Institute for Health and Care Excellence (NICE) consistently recommend oral ferrous salts (like ferrous sulphate) as first-line treatment for iron deficiency anemia.
  • Recent evidence supports "every-other-day" dosing for oral iron to improve absorption efficiency (by reducing hepcidin levels) and potentially reduce side effects, though daily dosing remains common practice.
• Evidence: Research continues to explore novel iron formulations (e.g., ferric maltol), but ferrous sulphate remains the gold standard for oral therapy due to its established efficacy and cost-effectiveness. The importance of elemental iron content for correct dosing is consistently emphasized.
• Controversies: Optimal dosing frequency (daily vs. alternate-day) for oral iron to maximize absorption and minimize side effects is an area of ongoing research, though both approaches are considered valid depending on patient factors. The role of pre-treatment hepcidin levels in guiding oral iron therapy is also being investigated.

Key References

• World Health Organization (WHO) Guidelines for the prevention and treatment of iron deficiency.
• American Society of Hematology (ASH) guidelines for iron deficiency anemia.
• National Institute for Health and Care Excellence (NICE) guidelines on anemia – iron deficiency.
• UpToDate: "Treatment of iron deficiency anemia in adults" and "Pharmacology of iron".
• Goodman & Gilman's The Pharmacological Basis of Therapeutics. 13th ed. McGraw-Hill Education; 2017. (For general pharmacology of iron).
• Cancelo-Hidalgo MJ, Castelo-Branco C, Palacios S, et al. Tolerability of different oral iron supplements: a systematic review. Curr Med Res Opin. 2013;29(3):291-303.
• Patterson AJ, Brown WJ, Roberts DC. Oral iron supplementation with and without ascorbic acid and plasma ferritin and iron. Eur J Clin Nutr. 2001;55(7):527-533.
• Moretti D, Goetze O, Burri J, et al. Oral iron supplements daily or every other day: a new strategy for improving iron status. Br J Haematol. 2015;168(4):534-543.